EP Patent

EP4236955A4 — METHOD FOR IMPROVING KIDNEY FUNCTION USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR

Assigned to Resverlogix Corp · Expires 2024-08-07 · 2y expired

What this patent protects

Patent listed against Jardiance.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: EP4236955A4
Jurisdiction: EP
Classification: —
Expires: 2024-08-07
Drug substance claim: No
Drug product claim: No
Assignee: Resverlogix Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.